Key Highlights
- Bioventix (LSE:BVXP) rose 2.13% on 2 October 2026 as investors positioned ahead of full-year results expected in late October.
- Royalties from Tau and other neuro antibodies rose five-fold to £150,000 in the first half, driven by Alzheimer's blood test research assays.
- The board said it remained confident in the outlook for the year ended 30 June 2026.
- Vitamin D remains the largest product, while troponin royalties are expected to benefit from an expanded US label on a partner's assay.
- The company is known for very high margins, with EBITDA margins around 75%, and a generous Dividend policy.
Bioventix (LSE:BVXP) Gains as Results Season Approaches
Shares in Bioventix plc (LSE:BVXP), the UK specialist in high-affinity sheep monoclonal antibodies for clinical diagnostics, rose 2.13% on Friday 2 October 2026. With the company's full-year results for the year to 30 June 2026 expected in late October, investors appear to be positioning for an update that could shift attention from mature product headwinds towards the fast-growing neurology opportunity.
The shares have had a volatile 12 months, trading in a 52-week range of roughly 1,300p to 3,020p, so the run-up to results is a period when buyers and sellers are particularly active.
Key Reasons Behind the 2.13% Gain
The first driver is momentum in neurology. In its interim results, Bioventix reported that royalties from Tau and other neuro antibodies rose five-fold to £150,000 from £30,000. These antibodies are used in research-use-only blood assays for Alzheimer's disease developed by major in vitro diagnostics groups and high-sensitivity platform companies. In the prior full year, Tau and neuro antibody sales had already quadrupled to £605,000.
The second driver is management confidence. At the half year, the board said trading remained in line with expectations and that it was confident in the outlook for the full year to 30 June 2026, even though currency movements and softer mature product sales weighed on the first half.
The third driver is the troponin opportunity. A partner's revised troponin assay label in the US is expected to drive greater assay use and royalties over time, and management previously guided that troponin growth should resume from 2026 onwards as new cardiac testing applications gain traction.
Why Investors Are Watching LSE:BVXP
Bioventix is a small, highly profitable Business with around 5.2 million shares in issue and EBITDA margins in the region of 75%. Its vitamin D antibody remains the largest Revenue line, generating around £6.6 million in the last full year, while thyroid, fertility and other mature antibodies provide a steady base.
The core debate centres on China, where government cost-reduction policies and a push for local Manufacturing have pressured volumes and pricing, with local companies seeking cheaper royalty-free alternatives. Management previously estimated around 2% of annual revenue could be at risk in the near term and a further 3% to 4% over the medium term.
Against that, the Alzheimer's diagnostic market is expanding rapidly as blood-based biomarkers gain acceptance. Bioventix continues to collaborate with the University of Gothenburg on Tau antibodies, including work on Tau tangle pathology, peripheral neuropathies and vascular dementia. It is also developing a water quality lateral flow test using caffeine and paracetamol as markers of human contamination in freshwater, with field trials planned during 2026.
Market and Social Media Sentiment
Investor forums have been closely tracking competing Tau biomarkers and partner assay developments, with several commentators hopeful of neurology news later this year. Director share dealings during April and June 2026 have also been noted, and the sizeable dividend remains a key attraction for income investors.
The upcoming results will be scrutinised for the size of the neuro Royalty line, the China impact and the level of the second interim dividend.
Risks to Monitor
Risks include continued pressure in China, currency movements, the Maturity of core products, the long timeline for Alzheimer's assays to move from research use to clinical diagnostics, and customer reporting accuracy on royalties.






Please wait processing your request...